{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:00:18Z","timestamp":1780916418571,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mesothelioma is a rare and aggressive tumour with dismal prognosis arising in the pleura and associated with asbestos exposure. Its incidence is on the rise worldwide. In selected patients with early-stage MPM, a maximal surgical cytoreduction in combination with additional antitumour treatment may be considered in selected patients assessed by a multidisciplinary tumor board. In patients with unresectable or advanced MPM, chemotherapy with platinum plus pemetrexed is the standard of care. Currently, no standard salvage therapy has been approved yet, but second-line chemotherapy with vinorelbine or gemcitabine is commonly used. Novel therapeutic approaches based on dual immunotherapy or chemotherapy plus immunotherapy demonstrated promising survival benefit and will probably be incorporated in the future.<\/jats:p>","DOI":"10.1007\/s12094-020-02532-2","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T12:04:54Z","timestamp":1612440294000},"page":"980-987","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9674-5554","authenticated-orcid":false,"given":"E.","family":"Nadal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bosch-Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cedr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Coves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Garc\u00eda-Campelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Guirado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"L\u00f3pez-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. L.","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"de Castro-Carpe\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"key":"2532_CR1","unstructured":"WHO ILO (ILO). Outline for the Development of National Programmes for Elimination of Asbestos-Related Diseases. 2014; Available from: https:\/\/www.who.int\/occupational_health\/publications\/asbestosdoc\/en\/. Accesed 30 Nov 2020"},{"key":"2532_CR2","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Abente G, Garc\u00eda-G\u00f3mez M, Men\u00e9ndez-Navarro A, Fern\u00e1ndez-Navarro P, Ramis R, Garc\u00eda-P\u00e9rez J, et al. Pleural cancer mortality in Spain: Time-trends and updating of predictions up to 2020. BMC Cancer. 2013","DOI":"10.1186\/1471-2407-13-528"},{"key":"2532_CR3","doi-asserted-by":"crossref","unstructured":"Galateau-Salle F, Churg A, Roggli V, Travis WD. The 2015 world health organization classification of tumors of the pleura: Advances since the 2004 Classification. J Thorac Oncol. 2016","DOI":"10.1016\/j.jtho.2015.11.005"},{"key":"2532_CR4","unstructured":"A.G. N, J.L. S, A.K. N, H.L. K, R.R. G, M. R-J, et al. EURACAN\/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. J Thorac Oncol. 2020"},{"key":"2532_CR5","doi-asserted-by":"crossref","unstructured":"Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, et al. Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. J Clin Oncol. 2018","DOI":"10.1200\/JCO.2018.36.15_suppl.8564"},{"key":"2532_CR6","doi-asserted-by":"crossref","unstructured":"Rice DC, Steliga MA, Stewart J, Eapen G, Jimenez CA, Lee JH, et al. Endoscopic Ultrasound-Guided Fine Needle Aspiration for Staging of Malignant Pleural Mesothelioma. Ann Thorac Surg. 2009","DOI":"10.1016\/j.athoracsur.2009.05.022"},{"key":"2532_CR7","doi-asserted-by":"crossref","unstructured":"Henderson DW, Reid G, Kao SC, Van Zandwijk N, Klebe S. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol. 2013","DOI":"10.1136\/jclinpath-2012-201303"},{"key":"2532_CR8","doi-asserted-by":"crossref","unstructured":"Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004","DOI":"10.1093\/annonc\/mdh059"},{"key":"2532_CR9","doi-asserted-by":"crossref","unstructured":"Armato SG, Nowak AK. Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1). J Thorac Oncol. 2018","DOI":"10.1016\/j.jtho.2018.04.034"},{"key":"2532_CR10","doi-asserted-by":"crossref","unstructured":"Rintoul RC, Ritchie AJ, Edwards JG, Waller DA, Coonar AS, Bennett M, et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): An open-label, randomised, controlled trial. Lancet. 2014","DOI":"10.1016\/S0140-6736(14)60418-9"},{"key":"2532_CR11","unstructured":"T. T, L. L-L, D. W, J.M. B, C. T, J. EE, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011"},{"key":"2532_CR12","doi-asserted-by":"crossref","unstructured":"Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014","DOI":"10.1016\/j.lungcan.2013.11.026"},{"key":"2532_CR13","doi-asserted-by":"crossref","unstructured":"Taioli E, Wolf AS, Flores RM. Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann Thorac Surg. 2015","DOI":"10.1016\/j.athoracsur.2014.09.056"},{"key":"2532_CR14","unstructured":"Clive AO, Taylor H, Dobson L, Wilson P, de Winton E, Panakis N, et al. Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial. Lancet Oncol. 2016"},{"key":"2532_CR15","doi-asserted-by":"crossref","unstructured":"Bayman N, Appel W, Ashcroft L, Baldwin DR, Bates A, Darlison L, et al. Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma: An open-label, multicenter, phase III randomized trial. J Clin Oncol. 2019","DOI":"10.1200\/JCO.18.01678"},{"key":"2532_CR16","doi-asserted-by":"crossref","unstructured":"Rimner A, Zauderer MG, Gomez DR, Adusumilli PS, Parhar PK, Wu AJ, et al. Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma. J Clin Oncol. 2016","DOI":"10.1200\/JCO.2016.67.2675"},{"key":"2532_CR17","doi-asserted-by":"crossref","unstructured":"de Perrot M, Feld R, Leighl NB, Hope A, Waddell TK, Keshavjee S, et al. Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2016","DOI":"10.1016\/j.jtcvs.2015.09.129"},{"key":"2532_CR18","doi-asserted-by":"crossref","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003","DOI":"10.1200\/JCO.2003.11.136"},{"key":"2532_CR19","doi-asserted-by":"crossref","unstructured":"Ceresoli GL, Zucali PA, Mencoboni M, Botta M, Grossi F, Cortinovis D, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer. 2013","DOI":"10.1038\/bjc.2013.368"},{"key":"2532_CR20","doi-asserted-by":"crossref","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial. Lancet. 2016","DOI":"10.1016\/S0140-6736(15)01238-6"},{"key":"2532_CR21","doi-asserted-by":"crossref","unstructured":"Ceresoli GL, Aerts JG, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck JP, et al. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Lancet Oncol. 2019","DOI":"10.1016\/S1470-2045(19)30532-7"},{"key":"2532_CR22","doi-asserted-by":"crossref","unstructured":"Popat S, Curioni-Fontecedro A, Dafni U, Shah R, O\u2019Brien M, Pope A, et al. A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9\u201315) PROMISE-meso trial. Ann Oncol. 2020","DOI":"10.1016\/j.annonc.2020.09.009"},{"key":"2532_CR23","doi-asserted-by":"crossref","unstructured":"Nowak AK, Lesterhuis WJ, Kok PS, Brown C, Hughes BG, Karikios DJ, et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol. 2020","DOI":"10.1016\/S1470-2045(20)30462-9"},{"key":"2532_CR24","doi-asserted-by":"crossref","unstructured":"Baas P, Scherpereel A, Nowak A, Fujimoto N, Peters S, Tsao A, et al. First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743. J Thorac Oncol. 2020","DOI":"10.1016\/j.jtho.2020.08.004"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-020-02532-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-020-02532-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-020-02532-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T13:56:59Z","timestamp":1618927019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-020-02532-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,4]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["2532"],"URL":"https:\/\/doi.org\/10.1007\/s12094-020-02532-2","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,4]]},"assertion":[{"value":"20 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"E. Nadal reports grant support from Roche and Pfizer and received personal fees from Bristol Myers Squibb (BMS), Merck Sharpe & Dohme (MSD), Lilly, Roche, Pfizer, Takeda, Boehringer Ingelheim, Amgen and AstraZeneca, outside the submitted work. J. Bosch-Barrera reports grants and personal fees from Roche-Genentech, grants from Pfizer and Pierre Fabre, personal fees from MSD, BMS, AstraZeneca, Novartis and Boehringer-Ingelheim, outside the submitted work. S. Cedr\u00e9s reports personal fees from BMS, F. Hoffmann La Roche, Pfizer, Boehringer Ingelheim, MSD and Amphera, outside the submitted work. J. Coves reports personal fees from Roche-Genentech, Pierre Fabre,\u00a0MSD,\u00a0BMS, AstraZeneca,\u00a0Novartis and Boehringer-Ingelheim, outside the submitted work. R. Garc\u00eda-Campelo reports personal fees from Roche-Genentech, Pfizer,\u00a0MSD,\u00a0BMS, Astrazeneca,\u00a0Novartis,\u00a0Takeda,\u00a0and Boehringer-Ingelheim, outside the submitted work. M. Guirado reports personal fees from AstraZeneca, Roche, BMS, Boehringer Ingelheim, outside the submitted work. R. L\u00f3pez-Castro participated in advisory boards from Novartis, BMS, Roche, Takeda, Boehringer Ingelheim and AstraZeneca and received travel grants from Novartis and Roche, outside the submitted work. A. L. Ortega has not conflict of interests. D. Vicente reports grant support forma Astra Zeneca and personal fees from Roche, Pfizer, Bristol Myers Squibb, Merck Sharpe and Dohme, Astra Zeneca, Amgen outside the submitted work. J. de Castro reports personal fees from Amgen, Astrazeneca, Boehringer-Ingelheim, Bristol Myers Squibb (BMS), Lilly, Merck Sharpe & Dohme (MSD), Novartis, Pfizer Roche-Genentech and Takeda, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study has been performed in accordance with the ethical standards of the Declaration of Helsinki and its later amendments. This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"For this type of study formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}